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Abstract
Circulating tumor cells offer an unprece-
dented window into the metastatic cascade, 
and to some extent can be considered as 
intermediates in the process of metastasis. 
They exhibit dynamic oscillations in epithe-
lial to mesenchymal plasticity and provide 
important opportunities for prognosis, ther-
apy response monitoring, and targeting of 
metastatic disease. In this manuscript, we 
review the involvement of epithelial-mesen-
chymal plasticity in the early steps of metas-
tasis and what we have learned about its 
contribution to genomic instability and 
genetic diversity, tumor progression and ther-
apeutic responses using cell culture, mouse 
models and circulating tumor cells enriched 
from patients.
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2.1  Defining Epithelial- 
Mesenchymal Plasticity
Cancer metastasis, the major cause of patient 
mortality, is a complex multi-step process in 
which tumor cells become invasive, intravasate 
into the blood, survive in the circulation, extrav-
asate out of the blood stream, and proliferate at 
the distal sites. During the early steps of metas-
tasis, tumor cells lose apico-basal polarity 
through disruption of cell-cell interactions and 
cytoskeletal remodeling to support invasion [1]. 
These changes are reminiscent of the normal 
physiological process, epithelial to mesenchy-
mal transition (EMT), that is required for gas-
trulation, neural crest cell migration, heart 
morphogenesis, organogenesis, and wound 
healing [1–7]. Utilization of EMT by cancer 
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cells to migrate, invade, and survive when non-
adherent provides an attractive model to under-
stand the critical steps involved in the initiation 
of metastasis. The process of canonical EMT in 
cancer cells is generally attributed to epigenetic 
changes that are thought to be largely reversible 
upon removal of EMT stimuli, resulting in the 
reversion of this phenotype through mesenchy-
mal-epithelial transition (MET). It is generally 
accepted that MET plays an important role in 
successful completion of the metastatic cascade 
with epithelial-like tumor formation [1, 7–11], 
and recently emerged controversies [12, 13] 
have been addressed [14, 15].
We will refer to these lineage switches as 
epithelial- mesenchymal plasticity (EMP) from 
this point forward to reflect the extensive bi- 
directional plasticity of the process. EMP phe-
notypes have been observed in cell culture and 
in mouse tumor models of breast, lung, pros-
tate, pancreatic, colorectal, and ovarian cancers 
[16–18]. Detection of EMP in patient-derived 
tumor tissue specimens, however, has been 
complicated by the presence of stromal cells 
which express high levels of mesenchymal 
markers. As such, despite the dramatic invasive 
and tumorigenic phenotypes observed in mouse 
xenografts expressing EMP-regulating master 
transcriptional factors, Snail, Twist, and Slug 
among others, the direct observation of EMP in 
the metastasis of human epithelial cancers has 
remained elusive. Recently, tumor cells at vari-
ous stages of EMP were detected in the blood 
of breast cancer patients, suggesting that EMP 
is not bimodal but is a continuous process [19]. 
These circulating tumor cells (CTCs) are 
extremely rare and are the putative precursors 
of metastasis. Therefore, defining EMP as a 
single dramatic transition between two states 
may be an oversimplification and may limit the 
study of EMP in some circumstances [7]. In 
this chapter, we will review the process of EMP, 
the evidence for EMP in clinical samples, its 
contribution to breast cancer dissemination 
(with a focus on the metastatic intermediates, 
CTCs), and the therapeutic implications associ-
ated with this process.
2.1.1  Epithelial-Mesenchymal 
Plasticity to Model the Early 
Steps of Metastasis
During EMP, epithelial cells within the primary 
tumor switch lineage to take on a more mesen-
chymal phenotype [1, 20], which is associated 
with morphological changes and molecular 
reprogramming [5, 21]. This consists of a series 
of sequential processes: the loss of apico-basal 
polarity due to cytoskeletal and junctional remod-
eling, increased cell migration as the result of 
decreased cell-cell adhesion and increased motil-
ity (sometimes at the cost of proliferation), and 
the acquisition of invasive properties such as pas-
sage through a basement membrane [1]. The 
basement membrane between the epithelia and 
nearby blood vessels is the first barrier encoun-
tered by invading cells [22]. Invasion requires 
breach of the basement membrane, then break-
down of the extracellular matrix in the stroma by 
proteases such as matrix metalloproteinases [23]. 
EMP regulates expression of many of the genes 
required for this breach of the basement mem-
brane and matrix. Upon arrival at the secondary 
site, MET then proceeds in the reverse order, 
with increased polarity and cell-cell adhesion 
leading to decreased cell migration and an epi-
thelial phenotype associated with increased pro-
liferation. The steps of this process are highlighted 
in Fig. 2.1.
2.1.2  Inducers and Effectors of EMP
EMP in both development and cancer is induced 
and maintained by a variety of signals: (i) extra-
cellular signals, (ii) master transcription factors, 
and (iii) post-transcriptional regulators. 
Extracellular signals regulating EMP consist of 
peptide growth factors (e.g. FGF, EGF, HGF, 
TGFβ), cytokines, differentiation factors (Wnt, 
Notch, SHH, NFκB pathways, RAS/receptor 
tyrosine kinases), and hormones secreted by the 
cancer cells themselves as well as the supporting 
cells in the tumor microenvironment [1, 7, 24–
30]. Additionally, hypoxia and extracellular com-
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ponents such as collagen also can induce EMP 
[1, 25–29, 31–33]. These extracellular signals are 
transduced to transcription factors that regulate 
the expression changes required to elicit 
epithelial- mesenchymal state change. The master 
transcriptional regulators of EMP include Snail/
Slug, Twist, and members of the Zeb transcrip-
tion factor family [1, 34]. EMP is also regulated 
by post-transcriptional processes including ubiq-
uitination, alternative splicing, and miRNAs that 
regulate protein translation, the most well charac-
terized being the miR-200 family which modu-
lates the expression of the (ZEB) proteins [1, 7, 
34–36].
Along with a multitude of additional modula-
tors and chromatin modifiers, these regulators 
coordinate the expression of proteins that main-
tain the epithelial state, apico-basal polarity, and 
Fig. 2.1 Metastatic cascade highlighting CTC and 
EMP characteristics. A small proportion of carcinoma 
cells exhibit epithelial mesenchymal plasticity, resulting 
in hybrid (E/M) phenotype rather than a distinctly mes-
enchymal phenotypes (M). These mesenchymally 
shifted cells are associated with loss of the basement 
membrane and migration / invasion into the tumor 
microenvironment, where they can remain dormant. 
Epithelial change in these cells is likely to underpin 
local recurrence, allowing a new colony to form. A 
higher proportion of mesenchymally shifted (E/M) cells 
is found in the vasculature as circulating tumor cells 
(CTCs), indicating their increased capacity for intrava-
sation and survival in the vasculature. A full spectrum of 
epithelial (E) to mesenchymal phenotypes is seen in the 
blood however, the hybrid phenotype dominates. CTC 
clusters containing cells at different stages of the EMP 
spectrum, and also normal immune cells and in some 
cases, tumor stromal cells, are also seen and have a 
higher prognostic value and a higher patho-biological 
potential. Dormant single cells / micrometastatic depos-
its can be seen in the bone marrow (depicted) or other 
metastatic sites. MET results in slightly altered gene 
expression profiles (EM)
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cell-cell adhesion, including Crumbs, PAR, 
Scribble, E-cadherin, α-catenin, γ-catenin/plako-
globin, and claudin. They also regulate proteins 
defining the mesenchymal state, cellular motility, 
and invasiveness, including N-cadherin, vimen-
tin, and fibronectin [1, 7, 19, 34]. Together, these 
many inputs create a broad and often redundant 
signaling network to induce and maintain these 
states of plasticity in tumor cells [1, 2, 5, 25–27, 
37–41].
2.1.3  EMP in Cancer Stem Cells 
and Drug Resistance
In addition to being involved in promoting 
metastasis, EMP has also been implicated in 
contributing to the maintenance of cancer stem 
cells (CSC). Like CSCs, cells undergoing EMP 
can survive under adverse conditions and exhibit 
resistance to chemotherapeutic interventions, 
although they do not necessarily self-renew 
[42]. Cells undergoing EMP coincidently 
acquire many CSC markers. In breast cancer, 
the presence of mesenchymal markers corre-
lated with the presence of CSC markers includ-
ing ALDH1, NANOG, OCT-4, and CD44 [43]. 
Double knockdown of the cancer stemness 
markers NANOG and OCT-4 reversed EMT in 
lung adenocarcinoma, while induction of these 
genes promoted EMT in breast cancer [43]. 
Similarly, knockdown of the OVOL2 transcrip-
tion factor in nasopharyngeal carcinoma cells 
decreased both EMT and stemness [44]. 
Upregulation of CSC markers and the appear-
ance of a CSC phenotype during EMP has been 
observed in cell lines, mouse models, and patient 
samples [43, 45–48]. However, EMP is not 
always associated with the appearance of CSC-
like properties. CSCs consist of both mesenchy-
mal and epithelial phenotypes under different 
contexts, while EMT is often associated with a 
more mesenchymal state [49]. Further, CSCs 
represent a minor population of all tumor cells, 
whereas EMP occurs in a much larger fraction 
of tumor cells suggesting that additional criteria 
are involved in defining the functional charac-
teristics of CSCs [50]. Further studies are 
required to better define the relationship between 
EMP and CSCs, specifically whether they repre-
sent a common phenomenon and if they are both 
induced and maintained through the same induc-
ers and pathways.
Across several cancer types, the mesenchy-
mal state is associated with increased drug 
resistance while the epithelial state is associated 
with increased sensitivity [34, 51–53]. In a 
mouse model of breast cancer, cells forced to 
revert to the epithelial state lost CSC markers 
and were increasingly sensitive to doxorubicin, 
paclitaxel, proteasome inhibitors, and MAPK/
EGFR inhibitors [54, 55]. Further, neoadjuvant 
chemotherapy in breast cancer has been shown 
to be ineffective against CTCs in the EMP state 
[56, 57]. EMP signatures were also found to be 
associated with treatment response and resis-
tance in non-small cell lung carcinoma, pancre-
atic, breast, and ovarian cancer [5, 12, 13, 30, 
58–60]. The mechanistic aspects of EMP 
thought to confer drug resistance are similar to 
those in CSCs and include elevated expression 
of antiapoptotic proteins and drug efflux trans-
porters and immunosuppression through the 
activities of EMP master transcription factors 
[50, 61].
2.1.4  Significance of EMP in Non- 
epithelial Cancers
While EMP is important for tumors of epithelial 
origin to migrate to the metastatic site, tumors of 
non-epithelial origin  – leukemias, lymphomas, 
myelomas, sarcomas, and brain and spinal cord 
cancers – do not necessarily encounter these bar-
riers. For some non-epithelial cancers, such as 
glioblastoma, markers of EMP are still induced 
by microglia and macrophages via NFkB and 
support invasiveness [30, 62, 63]. Further, of the 
four glioblastoma subtypes, the mesenchymal 
subtype is the most aggressive and radioresistant 
[64–66]. In sarcomas such as osteosarcoma and 
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rhabdomyosarcoma, where the cell of origin is 
already highly mesenchymal, further upregula-
tion of the EMP transcription factor ZEB1 has 
been observed compared to normal tissue, and 
SNAIL expression was associated with poorer 
overall survival [67–69]. Higher expression of 
epithelial E-cadherin is also associated with 
improved survival in bone and soft tissue sarco-
mas [70].
2.1.5  Contribution of EMP 
to Genomic Instability 
and Genetic Diversity
A series of studies published several years ago 
showed that mitosis during Drosophila and 
Xenopus embryogenesis is actively inhibited in 
cells undergoing gastrulation. Premature induc-
tion of proliferation before the completion of gas-
trulation in cells undergoing EMP results in 
extensive developmental abnormalities [71–74]. 
Recent studies show that this embryonic process 
is exploited by the tumor cells to drive genomic 
instability and diversity [75] – changes that can 
have profound consequences on tumor progres-
sion and drug responses. Although transitioning 
of epithelial cells to a mesenchymal state is 
reversible upon removal of the EMP inducers, the 
induced abnormalities in ploidy and genomic 
heterogeneity are heritable. The mechanistic clue 
to this incompatibility came from detailed pro-
teomic analysis, which revealed that several 
nuclear envelope proteins are suppressed as epi-
thelial cells transition to a mesenchymal state. 
Nuclear envelope proteins, in addition to provid-
ing the structural framework of the nucleus and 
selectively modulating the passage of molecules 
between the cytoplasm and the nucleoplasm, also 
play critical roles in orchestrating proper mitosis. 
Therefore, while the suppression of nuclear enve-
lope proteins reduces the rigidity of the nucleus 
to facilitate EMP-associated migration and inva-
sion, the requirement of these proteins for mitosis 
[76, 77] might also render their decrease during 
EMP incompatible with simultaneous prolifera-
tion. Subsequent studies show that clonal epithe-
lial populations spontaneously generate 
mesenchymal variants, which can revert to an 
epithelial phenotype [78] contributing to chro-
mosome instability and the selection of robust 
variants capable of forming metastatic tumors. 
Disruption of tissue architecture associated with 
this cell fate switch has also been implicated in 
maintaining the fidelity of chromosome segrega-
tion [79].
2.1.6  Mouse Models of EMP
The inherent plasticity of EMP makes unequivo-
cal determination of the lineage for a given cell 
difficult. Most studies evaluating the role of EMP 
in disease progression in  vivo have relied on 
xenograft mouse models and cultured cells. 
Experimental induction of EMP in cancer cells 
led to an increase in metastasis, and knockdown 
of EMP or premature induction of MET reduced 
metastasis [47, 80–82]. Interestingly, expression 
of the EMT-inducing homeobox transcription 
factor, Prrx1, led to EMT phenotypes in cultured 
cancer cells [47]. However, loss of Prrx1 in cul-
tured cells was required for efficient metastasis 
upon tail vein injection or orthotopic tumor for-
mation in mice [47]. Other studies utilized mouse 
models with intrinsic EMP reporters and gain-of- 
function or loss-of-function of EMP master tran-
scription factors [13, 20]. In skin-specific 
Twist1-inducible mice, Twist1 induction caused 
higher rates of squamous cell cancer develop-
ment upon treatment with a carcinogen [83]. 
Reversal of this Twist1 induction upon tumor cell 
dissemination significantly increased metastasis. 
Together with the Prrx1 data, this result strongly 
supports a role for MET in metastatic outgrowth 
[83]. Single-cell lineage tracing with reporter 
genes irreversibly activated by lineage-specific 
promoters have been used to query the fate of the 
cells experiencing EMP.  Reporter genes thus 
activated by epithelial/mesenchymal promoters 
have been used to track EMP in mouse models 
and monitor the change in cellular states during 
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the course of metastasis and tumor progression 
[84]. Breast cancer models have found that a 
small fraction of primary and metastatic tumor 
cells undergo EMT [12]. Conversely, pancreatic 
cancer models showed about half of tumor cells 
had undergone EMT, rarely occurring in prema-
lignant lesions [85]. However, given the complex 
signaling networks involved in promoting EMP, 
it is difficult to reach concrete conclusions based 
on studies that rely on a single marker in a given 
model, particularly in the context of the EMP 
hybrid phenotype, where the degree of induction 
may be less strong.
2.1.7  Detecting EMP in Clinical 
Samples
Although lineage tracing in humans is not possi-
ble and acquisition of serial samples is quite dif-
ficult, evaluation of epithelial and mesenchymal 
markers in patient-derived tissue provides a snap-
shot of EMP in the clinical setting. 
Immunohistochemistry (IHC) of human breast 
cancer samples with mesenchymal markers such 
as vimentin, N-cadherin, cell cycle, and tumor 
specific markers such as HER2, showed evidence 
for EMT in triple negative and basal-like tumors 
but not in invasive lobular carcinomas [86, 87]. 
RNA in situ hybridization (RNA-ISH) using 
multiple probes to detect both epithelial and mes-
enchymal transcripts in the same samples delin-
eated the ratios of epithelial and mesenchymal 
tumor cell populations at the single cell level in 
the primary tumors and draining lymph nodes of 
human breast cancer specimens [19]. While most 
tumor cells exhibited an epithelial phenotype, 
triple negative breast cancer was enriched for 
cells with mesenchymal markers, and all sub-
types contained rare cells with combined epithe-
lial and mesenchymal staining [19]. RNA-ISH 
analysis was also performed on CTCs from breast 
cancer patients, where it performed significantly 
better at detecting mesenchymal cells compared 
to standard cytokeratin approaches (discussed in 
more detail below) [19]. CTCs provide a non- 
invasive tool to monitor EMP in real time as 
patients progress through therapeutic 
interventions.
2.2  EMP in Circulating Tumor 
Cells
During metastasis, CTCs  – the putative meta-
static precursors  – travel through the blood. 
Although the majority of CTCs are destroyed in 
the blood through apoptosis, the remaining via-
ble cells reach and reside within distal sites in a 
dormant state until they adjust to the new micro-
environment and eventually proliferate. The rela-
tive accessibility of CTCs in the peripheral blood 
provides real time sampling of tumor cells to 
interrogate the contribution of EMP to metastasis 
and drug responsiveness [30].
Studies of CTCs provide some of the best evi-
dence for the involvement of EMP in promoting 
metastasis. Mesenchymal markers have been 
observed in CTCs from patients with glioblas-
toma, breast, liver, nasopharyngeal, colon, gas-
tric, bladder, pancreatic, and non-small cell lung 
cancers [7, 19, 30, 54, 56, 80, 88–97]. A summary 
of EMP studies in breast cancer CTCs is shown in 
Table 2.1. These studies showed that CTCs are a 
heterogeneous population and, as predicted, 
exhibit more mesenchymal characteristics com-
pared with the cells in the primary or metastatic 
tumors. A large fraction of individual CTCs was 
also found to express both epithelial and mesen-
chymal markers, suggesting that plasticity is a 
common component of the metastatic phenotype 
[7, 19, 30, 56, 80, 91–96]. Lineage tracing experi-
ments in animal models will be required to 
explore the stage of tissue residence or circulation 
at which CTCs undergo both EMT and MET [7].
2.2.1  Hybrid-EMP and CTC Clusters
Recent studies regarding EMP in CTCs address a 
longstanding dispute in the field: whether EMP 
should be defined as a binary process with epithe-
lial and mesenchymal endpoints as observed in 
most non-disease cases (with notable exceptions 
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of cohort migration as outlined below), or 
whether EMP is a spectrum phenotype with 
potentially stable higher-plasticity manifesta-
tions along the continuum from epithelial to mes-
enchymal phenotype [1, 53]. Highly-plastic cells 
with both epithelial and mesenchymal pheno-
types (hereafter referred to as hybrid-EMP) are 
observed in many CTCs as well as in  vivo; in 
fact, hybrid-EMP CTCs are more commonly 
observed than fully mesenchymal cells in many 
studies [8, 129]. Two recent studies of mouse 
pancreatic ductal adenocarcinoma (PDAC) and 
skin squamous cell cancer showed that these 
hybrid-EMP cells are more plastic than either 
epithelial or mesenchymal cells, with a higher 
ability to interconvert among the types in culture 
[8, 129]. Epigenetic, transcriptional, and post- 
transcriptional mechanisms were identified as 
regulating this interconversion, suggesting fur-
ther study is needed to devise a unified mecha-
nism for hybrid-EMP plasticity or to identify 
disease-specific mechanisms [8, 129]. Based on 
this data, we and others define EMP as a spec-
trum of phenotypes with highly plastic intercon-
version among the different states, with increased 
appreciation that the location of any particular 
cell along this continuum has important implica-
tions for both cancer and development [1, 7, 8, 
129–137]. However, it is important to note that 
while the existence and importance of hybrid- 
EMP is accepted, it is still unclear whether it rep-
resents an intermediate phase during EMP or a 
final state, and even whether the same signaling 
pathways at work during EMP are also responsi-
ble for hybrid-EMP [7, 8].
Practically, the label hybrid-EMP is assigned 
to varied states, which include cells that down-
regulate epithelial markers but do not upregulate 
the full complement of mesenchymal markers, as 
well as cells expressing both epithelial and mes-
enchymal markers [8, 129]. For example, cells 
with upregulation of mesenchymal processes 
such as loss of polarity and increased motility 
and invasion but without loss of cell-cell adhe-
sion or cell individualization. Indeed, although 
individual cell migration is a hallmark of EMT, 
recent studies have highlighted the presence of 
multicellular CTC clusters (up to 100 cells) in the 
circulation of patients with advanced cancers 
such as inflammatory breast cancer, and cohort 
migration is accepted as a frequent mode of inva-
sion [1, 51, 138–147]. Clusters are more effective 
at colonizing secondary sites than single CTCs 
and correlate with a worse prognosis [7, 19, 80, 
139]. Importantly, there is an association between 
CTC expression of mesenchymal markers and 
cluster formation. Many clusters are coated in 
platelets, which are a source of TGFβ and may 
help induce or maintain mesenchymal character-
istics [30, 148]. These clusters necessarily main-
tain cell-cell contacts and some epithelial-like 
expression (notably the desmosomal protein 
plakoglobin), suggesting that they exhibit the 
hybrid-EMP phenotype described above [8, 51, 
80, 149, 150]. Indeed, tumor spheres of hybrid- 
EMP mouse prostate cancer cells exhibited col-
lective cell migration and cluster delamination 
while fully mesenchymal spheres only showed 
single-cell invasion [8]. It is not clear whether 
hybrid-EMP clusters are composed of a homog-
enous population of hybrid-EMP CTCs versus a 
mixed population of epithelial CTCs and mesen-
chymal CTCs [80]. However it is important to 
note that lineage tracing and tumor transplanta-
tion experiments show that CTC clusters do not 
form in the bloodstream through aggregation of 
single CTCs, but originate from polyclonal pri-
mary tumors, suggesting that the hybrid-EMP 
phenotype is established before invasion into the 
circulation [139, 151]. Although these clusters 
may seem impossibly large for invasion or 
extravasation through the blood vessel into the 
secondary tissue, studies have shown that CTC 
clusters can traverse the capillaries of Zebrafish 
by rapid reorganization into single-file chains 
[140]. Finally, although cohort migration is high-
lighted in the study of cancer CTCs, it should be 
noted that similar modes of invasion occur during 
development, wound healing, and mammary 
reorganization in some species, underscoring the 
fact that this hybrid-EMP phenotype is not 
restricted to the cancer environment [1].
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2.2.2  Role of EMP in CTCs 
During Progression 
and Therapeutic Response
The implications of hybrid-EMP phenotypes on 
tumor histology and prognosis are significant. 
Hybrid-EMP cells are detected in both primary 
and metastatic tumors and are particularly preva-
lent in individual and clustered CTC populations 
as noted above [19]. Single-cell evaluation of 
both EMP markers and tumor-specific markers 
(such as HER2) in breast cancer confirm that 
these hybrid-EMP cells are tumor-derived [19]. 
Mesenchymal mouse PDAC tumors were poorly 
differentiated while hybrid-EMP tumors were 
moderately to well-differentiated [8]. Similar 
results are observed in human poorly differenti-
ated quasi-mesenchymal, squamous, or basal- 
like PDAC tumors versus well-differentiated 
classical/exocrine-like, classical, or pancreatic 
progenitor/ADEX tumors [8, 152–154]. The pro-
portion of breast cancer CTCs with fully epithe-
lial, predominantly mesenchymal, or hybrid-EMP 
seems to be dependent on tumor type and stage, 
consistent with data for primary and metastatic 
tumor cells. Pre-invasive ductal carcinoma in situ 
(DCIS) lesions exhibit exclusively epithelial phe-
notypes, while invasive breast cancers contain 
rare hybrid-EMP cells, suggesting incomplete 
MET [19]. Further, CTCs from patients with lob-
ular type (ER+/PR+) cancers were predominantly 
epithelial while CTCs from patients with HER2+ 
or triple negative breast cancers were predomi-
nantly mesenchymal [19].
Studies show that EMP phenotypes in CTCs 
indicate poor prognosis and resistance to therapy. 
Hybrid-EMP mouse skin cancer cells produced 
more metastasis after tail vein injection than 
fully mesenchymal cells [129]. In humans, EMP 
CTCs confer poor prognosis in breast, prostate, 
liver, colorectal, head and neck, pancreatic, 
endometrial, and lung cancers [155]. Hybrid-
EMP cells are more anoikis-resistant and drug-
resistant [53, 156], giving them a better chance 
of metastatic colonization. Although the signal-
ing pathways mediating anoikis resistance are 
not fully understood, EMP markers such as 
TGFβ, Twist, Snail, and miR200 have also been 
shown to have effects on survival in circulation 
[157, 158]. This is particularly significant to 
breast cancer treatment, as apoptosis is the main 
inducer of regression in systemic therapy and 
resistance of disseminated tumor cells to apopto-
sis is correlated with worse prognosis [159]. 
EMP CTCs were also associated with chemo-
therapy or radiotherapy resistance in ovarian, 
breast, and colorectal cancer [109, 160, 161]. 
Interestingly, when one breast cancer patient was 
followed longitudinally, mesenchymal- CTCs 
decreased with therapy response and then 
increased upon development of resistance, a phe-
nomenon that was observed over two successive 
rounds of treatment. This increase in mesenchy-
mal-CTCs was accompanied by the appearance 
of CTC-clusters [19].
2.2.3  The Influence of EMP on CTC 
Isolation Technologies
The plasticity of mixed epithelial and mesenchy-
mal CTC phenotypes in the blood has been highly 
consequential in defining the capture efficiency 
of antibody-based CTC isolation approaches that 
rely on the expression of the epithelial marker 
EpCAM on the surface of tumor cells. The only 
FDA approved technique for in vitro diagnostic 
use, CellSearch®, (Veridex, Menarini Silicon 
Biosystems) uses immunomagnetic beads coated 
with antibodies against EpCAM. Other CTC iso-
lation modalities rely on physical characteristics 
such as size, density, deformability, and charge. 
However, because CTCs are highly heteroge-
neous and many CTCs exhibit a hybrid-EMP or 
fully mesenchymal phenotype, enrichment by a 
single epithelial surface marker or physical char-
acteristic may not be sufficient to capture the full 
array of CTCs in the blood [7]. To overcome this 
limitation, techniques using multiple antibodies 
that mark epithelial and mesenchymal states (e.g. 
a combination of EpCAM, cytokeratin, and 
vimentin) and tumor-specific cell surface mark-
ers including HER2 and EGFR have been more 
effective in sampling the different populations of 
CTCs circulating in the blood [19]. However, 
these “double positive” isolation technologies 
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still fail to enrich for hybrid-EMP CTCs that 
express neither epithelial nor mesenchymal com-
monly examined markers [8]. Negative depletion 
of leukocytes with antibodies directed against 
white blood cells provides an efficient method to 
overcome the limitations posed by positive selec-
tion. These technologies rely on a permissive 
size-based separation to eliminate red blood cells 
followed by immunomagnetic depletion of white 
blood cells with CD45 antibodies [162–165]. 
They are considered negative selection because 
they enrich for CTCs based on known properties 
of the other cellular components of the blood, 
rather than making assumptions about CTC phe-
notypes that could bias the population of CTCs 
after isolation. The capability of each technique 
to isolate epithelial, mesenchymal, and hybrid-
EMP CTCs is shown in Table  2.2. They each 
have their strengths and weaknesses, which are 
important to appreciate, however to date there in 
no universally accepted preferred method that 
allows comprehensive capture of all CTCs.
Table 2.2 Methods of CTC isolation and EMP recovery
Method Name
Detection of Epithelial (E), 
Mesenchymal (M), or Hybrid 
(H) CTCs References
Physical separation
Size based filtration/microfluidics Microcavity array 
(MCA); FAST disc; 
CellSieve
E = M = H [166–168]
Density based centrifugation Ficoll; OncoQuick E = M = H [169]
Size and deformability ISET®; Celsee M > H > E [170, 171]
Cell surface charge PEG E = M = H [172]
Density based centrifugation followed by 
invasion
CAM M > E [173]
Negative selection





Density separation of tetrameric antibody 
complexes for CD45, CD66b and 
glycophorin
RARE E = M = H [164]
Density gradient separation then 




Cell surface vimentin CSV 84-1 M [118]
Cell surface EpCAM and FRα unnamed E = M > H [174]
High throughput microscopy for 
immunofluorescence or FISH
Epic CTC Platform®; 
FAST
E = M > H [175–177]
EpCAM based immunomagnetic 
separation
CellSearch® E [170]






Sized based filtration then EpCAM, CK, 
vimentin, and twist RNA-ISH
CanPatrol E = M > H [94]
Flow Cytometry for surface epithelial 
markers
IE/FC E [182]




Size based filtration FMSA; Cluster-Chip M = H > E [143, 144, 
184]
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2.3  Clinical Correlates 
and Future Study




The functional connections between EMP and 
cancer progression are well-established and are 
supported by prognostic correlations observed in 
patient-derived samples. In ovarian cancer, higher 
EMP scores are correlated with worse prognosis, 
both for overall and disease-free survival [156]. 
In metastatic breast, pancreatic, and hepatocellu-
lar carcinomas, increases in EMP CTCs are asso-
ciated with progression, poor therapeutic 
response, metastasis, and worse prognosis while 
patients responding to therapy show a decrease in 
EMP CTCs [7, 19, 43, 80, 93, 95, 127]. The 
hybrid-EMP phenotype predominates in many 
cancer types, including aggressive breast cancer 
and melanoma, and may therefore indicate a 
worse prognosis than tumors with a purely mes-
enchymal phenotype [80]. Further, cancer cells 
exhibiting hybrid-EMP were more plastic, and 
more efficient in tumor budding, invasion, stem-
ness, CTC cluster formation, and drug resistance 
[34, 51]. Because CTCs are hematogenously cir-
culating and represent many stages of metastasis, 
evaluation of EMP in CTCs may have clinical 
relevance as a biomarker [93]. However, these 
studies are still preliminary and the prognostic 
value of EMP CTCs in monitoring therapeutic 
resistance or progression has not been fully deter-
mined and no recommendation for clinical moni-
toring has been issued [127, 185].
2.3.2  Prevention or Reversal of EMP 
as a Therapeutic Target
In addition to serving as a biomarker, EMP may 
be an attractive therapeutic target to slow or halt 
metastasis. Current clinical trials aiming to pre-
vent or reverse EMT are testing TGFβ inhibition 
(LY2157299  in glioblastoma and hepatocellular 
carcinoma), clusterin (a TGFβ mediator) inhibi-
tion (AB-16B5 in advanced solid tumors), plate-
let inhibition (aspirin in metastatic breast and 
colorectal cancer), AXL inhibition (TP-0903  in 
refractory solid tumors), and Src kinase inhibi-
tion, with mixed results [186–192]. Reversing 
transition to a mesenchymal state through re- 
differentiation could reduce invasiveness and 
resensitize cells to current therapies. However, 
there are concerns associated with therapies tar-
geting EMP. First, MET is likely required for out-
growth at the secondary site and therefore such a 
treatment may actually support metastasis, pos-
sibly through reactivating dormant tumor cells 
[47, 83, 193–196]. Indeed, knockdown of the 
EMP transcription factors PRRX1 and Twist1 in 
breast cancer cells increased lung metastasis in 
mice [47]. Reciprocally, induction of Twist1 in a 
skin cancer model inhibited metastatic outgrowth 
[83]. Second, even if we could be confident that 
EMP inhibition would not be detrimental to the 
patient, the benchmarks for such a reversal are 
unclear. As described, EMP is not a single pheno-
type, but a broad array of intermediate states in 
different cells. It is therefore difficult to deter-
mine how far along the EMP continuum to 
reverse the cells, and how to achieve consistent 
effects in such a heterogeneous population. The 
best course of action will likely be different for 
different contexts and cancer types, further com-
plicating the issue [7].
2.4  Controversies
Two papers published in 2015 using lineage trac-
ing mouse models raised doubts about whether 
EMP is strictly necessary for metastasis in vivo 
(although they maintain support for a role in che-
moresistance) [12, 13, 30, 197]. However, numer-
ous papers in response to these findings have 
drawn on decades of research in support of a role 
for EMP in metastasis, pointing out that the com-
plexity of this dynamic process  – with interac-
tions between multiple transcription factors, 
important intermediate and hard to detect pheno-
types, and necessary plasticity between epithelial 
and mesenchymal states to complete the meta-
static cycle – makes it very difficult to interpret 
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the results of a single lineage tracing model [7, 
14, 15, 80, 195]. Future models of greater nuance 
relying on multiple EMP markers and single cell 
analysis will help to fully understand the role of 
EMP in metastasis.
2.5  Remaining Questions
Despite over 30 years of study, new and old ques-
tions remain to be addressed to clarify the role 
that EMP, and therefore CTCs and CTC clusters, 
play in metastasis. As we continue to probe fur-
ther into the impact of EMP on tumorigenesis 
and metastasis, our increased awareness of the 
hybrid-EMP phenotypes exhibited by many 
tumor cells, but especially CTCs, will provide 
more insight into this process. Further studies are 
needed to define how many distinct subtypes 
there are within the continuum, how stable/plas-
tic these subtypes are relative to each other, and 
whether their functional characteristics remain 
the same across different cancer types. This will 
require a collaborative decision regarding the 
markers of epithelial and mesenchymal pheno-
types, the setting of thresholds for expression, 
and establishing of assays that mimic intercon-
version between states in patients. It will also 
need to be determined whether these hybrid-EMP 
subtypes are best modeled as a continuum or as a 
trans-differentiation. This will be informed by 
studies examining how cells transition between 
the subtypes, including examinations of both 
transcriptional and post-transcriptional 
regulations.
Beyond defining hybrid-EMP, it is becoming 
clear that hybrid-EMP in CTCs and tumor cells 
alike is correlated with a worse prognosis and 
higher metastatic potential that fully epithelial or 
mesenchymal cells [53, 129]. It remains to be 
determined whether it is the hybrid-EMP cells 
themselves, or just the existence of a more het-
erogeneous population of tumor cells, that is the 
cause of this observation. On the one hand, 
metastasis requires both mesenchymal and epi-
thelial processes, and cells locked into a mesen-
chymal state may fail to initiate a tumor in the 
secondary site. It is possible that hybrid-EMP 
CTCs encompass the population of CSCs that are 
the crucial determinants of successful tumor re- 
initiation. On the other hand, different cancer 
types and individual cancers exhibit different lev-
els of hybrid-EMP, and yet many cancers are 
metastatic. With the recent identification of CTC 
clusters and the appreciation of their higher met-
astatic potential, it is possible that heterogeneous 
clusters of CTCs, containing cells with epithelial, 
hybrid-EMP, and mesenchymal phenotypes can 
form and cooperatively make the metastatic jour-
ney, with the mesenchymal cells “shepherding” 
the epithelial cells to their destination. Our ability 
to address these and other mechanistic questions 
will be aided by technological developments. 
Already, CTC isolation technologies have given 
us an opportunity to study some of these ques-
tions in the most appropriate setting  – invaded 
cells that are the putative precursors of metasta-
sis. Because these rare cells must be enriched, it 
will be crucial to select the appropriate isolation 
technology so that our evaluation of the breadth 
of EMP phenotypes in CTCs is not biased. To 
confidently accomplish this, we will need to stan-
dardize epithelial, mesenchymal, and CTC mark-
ers. Upon isolation of a physiologically relevant 
CTC population, advances in genomics and pro-
teomics will allow for comprehensive mapping 
of transcriptional, epigenetic, and post- 
transcriptional differences in EMP phenotypes in 
individual CTCs and throughout disease progres-
sion. Finally, although CTCs are the metastati-
cally competent population, upon isolation they 
still provide only a snapshot in the EMP progres-
sion of that cell. As with all EMP studies, animal 
models and lineage tracing technologies will be 
crucial to visualize and ultimately understand the 
implications of EMP on metastasis in vivo.
References
 1. Savagner P.  Epithelial-mesenchymal transitions: 
from cell plasticity to concept elasticity. Curr 
Top Dev Biol. 2015;112:273–300. https://doi.
org/10.1016/bs.ctdb.2014.11.021.
 2. Lim J, Thiery JP.  Epithelial-mesenchymal transi-
tions: insights from development. Development. 
2012;139(19):3471–86. https://doi.org/10.1242/
dev.071209.
2 Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis
26
 3. Nakaya Y, Sheng G. Epithelial to mesenchymal tran-
sition during gastrulation: an embryological view. 
Develop Growth Differ. 2008;50(9):755–66. https://
doi.org/10.1111/j.1440-169X.2008.01070.x.
 4. Solnica-Krezel L, Sepich DS.  Gastrulation: mak-
ing and shaping germ layers. Annu Rev Cell Dev 
Biol. 2012;28:687–717. https://doi.org/10.1146/
annurev-cellbio-092910-154043.
 5. Yu M, Smolen GA, Zhang J, Wittner B, Schott 
BJ, Brachtel E, et  al. A developmentally regulated 
inducer of EMT, LBX1, contributes to breast can-
cer progression. Genes Dev. 2009;23(15):1737–42. 
https://doi.org/10.1101/gad.1809309.
 6. Shaw TJ, Martin P.  Wound repair: a showcase 
for cell plasticity and migration. Curr Opin Cell 
Biol. 2016;42:29–37. https://doi.org/10.1016/j.
ceb.2016.04.001.
 7. Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 
2016. Cell. 2016;166(1):21–45. https://doi.
org/10.1016/j.cell.2016.06.028.
 8. Aiello NM, Maddipati R, Norgard RJ, Balli D, Li 
J, Yuan S, et  al. EMT subtype influences epithe-
lial plasticity and mode of cell migration. Dev 
Cell. 2018;45:681-95.e4. https://doi.org/10.1016/j.
devcel.2018.05.027.
 9. Bedi U, Mishra VK, Wasilewski D, Scheel C, 
Johnsen SA.  Epigenetic plasticity: a central regu-
lator of epithelial-to-mesenchymal transition in 
cancer. Oncotarget. 2014;5(8):2016–29. https://doi.
org/10.18632/oncotarget.1875.
 10. McDonald OG, Wu H, Timp W, Doi A, Feinberg 
AP.  Genome-scale epigenetic reprogramming dur-
ing epithelial-to-mesenchymal transition. Nat 
Struct Mol Biol. 2011;18(8):867–74. https://doi.
org/10.1038/nsmb.2084.
 11. Micalizzi DS, Maheswaran S, Haber DA. A conduit 
to metastasis: circulating tumor cell biology. Genes 
Dev. 2017;31(18):1827–40. https://doi.org/10.1101/
gad.305805.117.
 12. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong 
ST, et  al. Epithelial-to-mesenchymal transition is 
not required for lung metastasis but contributes to 
chemoresistance. Nature. 2015;527(7579):472–6. 
https://doi.org/10.1038/nature15748.
 13. Zheng X, Carstens JL, Kim J, Scheible M, Kaye 
J, Sugimoto H, et  al. Epithelial-to-mesenchymal 
transition is dispensable for metastasis but induces 
chemoresistance in pancreatic cancer. Nature. 
2015;527:525–30. https://doi.org/10.1038/
nature16064.
 14. Ye X, Brabletz T, Kang Y, Longmore GD, Nieto 
MA, Stanger BZ, et al. Upholding a role for EMT 
in breast cancer metastasis. Nature. 2017;547:E1–6. 
https://doi.org/10.1038/nature22816.
 15. Aiello NM, Brabletz T, Kang Y, Nieto MA, 
Weinberg RA, Stanger BZ.  Upholding a role for 
EMT in pancreatic cancer metastasis. Nature. 
2017;547(7661):E7–8. https://doi.org/10.1038/
nature22963.
 16. Boyer B, Tucker GC, Valles AM, Franke WW, 
Thiery JP.  Rearrangements of desmosomal and 
cytoskeletal proteins during the transition from epi-
thelial to fibroblastoid organization in cultured rat 
bladder carcinoma cells. J Cell Biol. 1989;109(4 Pt 
1):1495–509.
 17. Weidner KM, Behrens J, Vandekerckhove J, 
Birchmeier W. Scatter factor: molecular characteris-
tics and effect on the invasiveness of epithelial cells. 
J Cell Biol. 1990;111(5 Pt 1):2097–108.
 18. Jolly MK, Ward C, Eapen MS, Myers S, Hallgren 
O, Levine H, et al. Epithelial–mesenchymal transi-
tion, a spectrum of states: role in lung development, 
homeostasis, and disease. Dev Dyn. 2018;247:346–
58. https://doi.org/10.1002/dvdy.24541.
 19. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, 
Ting DT, et al. Circulating breast tumor cells exhibit 
dynamic changes in epithelial and mesenchymal 
composition. Science. 2013;339:580–4. https://doi.
org/10.1126/science.1228522.
 20. Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, 
Ng Eaton E, et  al. Distinct EMT programs control 
normal mammary stem cells and tumour- initiating 
cells. Nature. 2015;525:256–60. https://doi.
org/10.1038/nature14897.
 21. Hay ED.  The mesenchymal cell, its role in the 
embryo, and the remarkable signaling mechanisms 
that create it. Dev Dyn. 2005;233(3):706–20. https://
doi.org/10.1002/dvdy.20345.
 22. Sherwood DR.  Cell invasion through basement 
mem- branes : an anchor of understanding. Trends 
Cell Biol. 2006;16:250–6. https://doi.org/10.1016/j.
tcb.2006.03.004.
 23. De Wever O, Mareel M. Role of tissue stroma in can-
cer cell invasion. J Pathol. 2003;200:429–47. https://
doi.org/10.1002/path.1398.
 24. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, 
Stanley ER, et al. A paracrine loop between tumor 
cells and macrophages is required for tumor 
cell migration in mammary tumors. Cancer Res. 
2004;64(19):7022–9. https://doi.org/10.1158/0008-
5472.CAN-04-1449.
 25. De Craene B, Berx G.  Regulatory networks defin-
ing EMT during cancer initiation and progression. 
Nat Rev Cancer. 2013;13(2):97–110. https://doi.
org/10.1038/nrc3447.
 26. Nieto MA, Cano A.  The epithelial- mesenchymal 
transition under control: global programs to regu-
late epithelial plasticity. Semin Cancer Biol. 
2012;22(5-6):361–8. https://doi.org/10.1016/j.
semcancer.2012.05.003.
 27. Zheng H, Kang Y.  Multilayer control of the EMT 
master regulators. Oncogene. 2014;33(14):1755–63. 
https://doi.org/10.1038/onc.2013.128.
 28. Dong L, Ge XY, Wang YX, Yang LQ, Li SL, Yu 
GY, et al. Transforming growth factor-beta and epi-
thelial-mesenchymal transition are associated with 
pulmonary metastasis in adenoid cystic  carcinoma. 
Oral Oncol. 2013;49(11):1051–8. https://doi.
org/10.1016/j.oraloncology.2013.07.012.
R. Burr et al.
27
 29. Giannoni E, Parri M, Chiarugi P.  EMT and oxi-
dative stress: a bidirectional interplay affect-
ing tumor malignancy. Antioxid Redox Signal. 
2012;16(11):1248–63. https://doi.org/10.1089/
ars.2011.4280.
 30. Micalizzi DS, Haber DA, Maheswaran S.  Cancer 
metastasis through the prism of epithelial-to- 
mesenchymal transition in circulating tumor 
cells. Mol Oncol. 2017;11(7):770–80. https://doi.
org/10.1002/1878-0261.12081.
 31. Choi HY, Yoo Y, Kim J-H, Dayem AA, Yee C, 
Yang G-M, et  al. Hydrodynamic shear stress pro-
motes epithelial-mesenchymal transition by down-
regulating ERK and GSK3β activities. Breast 
Cancer Res. 2019;21:1–20. https://doi.org/10.1186/
s13058-018-1071-2.
 32. Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, 
Bhagwat N, Pham MN, et  al. Metastatic progres-
sion is associated with dynamic changes in the local 
microenvironment. Nat Commun. 2016;7:12819. 
https://doi.org/10.1038/ncomms12819.
 33. Jung HY, Fattet L, Yang J.  Molecular pathways: 
linking tumor microenvironment to epithelial- 
mesenchymal transition in metastasis. Clin 
Cancer Res. 2015;21(5):962–8. https://doi.
org/10.1158/1078-0432.CCR-13-3173.
 34. Garg M. Epithelial plasticity and metastatic cascade. 
Expert Opin Ther Targets. 2018;22:5–7. https://doi.
org/10.1080/14728222.2018.1407312.
 35. Voutsadakis IA.  The ubiquitin-proteasome sys-
tem and signal transduction pathways regu-
lating Epithelial Mesenchymal transition of 
cancer. J  Biomed Sci. 2012;19:67. https://doi.
org/10.1186/1423-0127-19-67.
 36. Bracken CP, Scott HS, Goodall GJ.  A network- 
biology perspective of microRNA function 
and dysfunction in cancer. Nat Rev Genet. 
2016;17(12):719–32. https://doi.org/10.1038/
nrg.2016.134.
 37. Lamouille S, Xu J, Derynck R.  Molecular mecha-
nisms of epithelial-mesenchymal transition. Nat 
Rev Mol Cell Biol. 2014;15(3):178–96. https://doi.
org/10.1038/nrm3758.
 38. Savagner P.  Leaving the neighborhood: molecular 
mechanisms involved during epithelial- mesenchymal 
transition. Bioessays. 2001;23(10):912–23. https://
doi.org/10.1002/bies.1132.
 39. Yang J, Weinberg RA. Epithelial-mesenchymal tran-
sition: at the crossroads of development and tumor 
metastasis. Dev Cell. 2008;14(6):818–29. https://
doi.org/10.1016/j.devcel.2008.05.009.
 40. Casas E, Kim J, Bendesky A, Ohno-Machado L, 
Wolfe CJ, Yang J. Snail2 is an essential mediator of 
Twist1-induced epithelial mesenchymal transition 
and metastasis. Cancer Res. 2011;71(1):245–54. 
https://doi.org/10.1158/0008-5472.CAN-10-2330.
 41. Dhasarathy A, Phadke D, Mav D, Shah RR, Wade 
PA. The transcription factors Snail and Slug activate 
the transforming growth factor-beta signaling path-
way in breast cancer. PLoS One. 2011;6(10):e26514. 
https://doi.org/10.1371/journal.pone.0026514.
 42. Yamauchi T, Fernandez JRE, Imamura CK, 
Yamauchi H, Jinno H, Takahashi M, et al. Dynamic 
changes in CD44v-positive cells after preoperative 
anti-HER2 therapy and its correlation with patho-
logic complete response in HER2-positive breast 
cancer. Oncotarget. 2018;9:6872–82. https://doi.
org/10.18632/oncotarget.23914.
 43. Markiewicz A, Nagel A, Szade J, Majewska H, 
Skokowski J, Seroczynska B, et al. Aggressive phe-
notype of cells disseminated via hematogenous and 
lymphatic route in breast cancer patients. Transl 
Oncol. 2018;11:722–31. https://doi.org/10.1016/j.
tranon.2018.03.006.
 44. Qi XK, Han HQ, Zhang HJ, Xu M, Li L, Chen L, 
et al. OVOL2 links stemness and metastasis via fine- 
tuning epithelial-mesenchymal transition in nasopha-
ryngeal carcinoma. Theranostics. 2018;8:2202–16. 
https://doi.org/10.7150/thno.24003.
 45. Mani SA, Guo W, Liao M-JJ, Eaton EN, Ayyanan 
A, Zhou AY, et al. The epithelial-mesenchymal tran-
sition generates cells with properties of stem cells. 
Cell. 2008;133:704–15. https://doi.org/10.1016/j.
cell.2008.03.027.
 46. Al-Hajj M, Wicha MS, Benito-Hernandez A, 
Morrison SJ, Clarke MF.  Prospective identifica-
tion of tumorigenic breast cancer cells. Proc Natl 
Acad Sci U S A. 2003;100(7):3983–8. https://doi.
org/10.1073/pnas.0530291100.
 47. Ocaña OH, Córcoles R, Fabra Á, Moreno-Bueno 
G, Acloque H, Vega S, et  al. Metastatic coloni-
zation requires the repression of the epithelial- 
mesenchymal transition inducer Prrx1. Cancer 
Cell. 2012;22:709–24. https://doi.org/10.1016/j.
ccr.2012.10.012.
 48. Kroger C, Afeyan A, Mraz J, Eaton EN, Reinhardt F, 
Khodor YL, et al. Acquisition of a hybrid E/M state 
is essential for tumorigenicity of basal breast cancer 
cells. Proc Natl Acad Sci U S A. 2019;116(15):7353–
62. https://doi.org/10.1073/pnas.1812876116.
 49. Grosse-Wilde A, D'Hérouël AF, McIntosh E, 
Ertaylan G, Skupin A, Kuestner RE, et al. Stemness 
of the hybrid epithelial/mesenchymal state in breast 
cancer and its association with poor survival. PLoS 
ONE. 2015;10:1–28. https://doi.org/10.1371/jour-
nal.pone.0126522.
 50. Shibue T, Weinberg RA. EMT, CSCs, and drug resis-
tance: the mechanistic link and clinical implications. 
Nat Rev Clin Oncol. 2017;14:611–29. https://doi.
org/10.1038/nrclinonc.2017.44.
 51. Basu S, Cheriyamundath S, Ben-Ze’ev A.  Cell–
cell adhesion: linking Wnt/β-catenin signaling 
with partial EMT and stemness traits in tumori-
genesis. F1000Research. 2018;7:1488. https://doi.
org/10.12688/f1000research.15782.1.
2 Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis
28
 52. Redfern AD, Spalding LJ, Thompson EW.  The 
Kraken Wakes: induced EMT as a driver of tumour 
aggression and poor outcome. Clin Exp Metastasis. 
2018;35(4):285–308. https://doi.org/10.1007/
s10585-018-9906-x.
 53. Jolly MK, Mani SA, Levine H.  Hybrid epithelial/
mesenchymal phenotype(s): the ‘fittest’ for metas-
tasis? Biochim Biophys Acta. 2018;1870:151–7. 
https://doi.org/10.1016/j.bbcan.2018.07.001.
 54. Markiewicz A, Zaczek AJ.  The landscape of 
circulating tumor cell research in the con-
text of epithelial- mesenchymal transition. 
Pathobiology. 2017;84:264–83. https://doi.
org/10.1159/000477812.
 55. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, 
Hedman K, Ravdel L, et  al. Restoring E-cadherin 
expression increases sensitivity to epidermal 
growth factor receptor inhibitors in lung cancer cell 
lines. Cancer Res. 2006;66(2):944–50. https://doi.
org/10.1158/0008-5472.CAN-05-1988.
 56. Choynzonov E, Savelieva O, Slonimskaya E, 
Perelmuter V, Tashireva L, Tarabanovskaya N, 
et  al. Heterogeneity of circulating tumor cells 
in neoadjuvant chemotherapy of breast cancer. 
Molecules. 2018;23:727. https://doi.org/10.3390/
molecules23040727.
 57. Li H, Smolen GA, Beers LF, Xia L, Gerald W, Wang 
J et al. Adenosine transporter ENT4 is a direct target 
of EWS / WT1 translocation product and is highly 
expressed in desmoplastic small round cell tumor 
PLoS ONE. 2008;3. https://doi.org/10.1371/journal.
pone.0002353.
 58. Byers DE, Alexander-Brett J, Patel AC, Agapov E, 
Dang-Vu G, Jin X, et al. Long-term IL-33-producing 
epithelial progenitor cells in chronic obstructive lung 
disease. J Clin Invest. 2013;123(9):3967–82. https://
doi.org/10.1172/JCI65570.
 59. Bryant JL, Britson J, Balko JM, Willian M, Timmons 
R, Frolov A, et  al. A microRNA gene expression 
signature predicts response to erlotinib in epithe-
lial cancer cell lines and targets EMT. Br J Cancer. 
2012;106(1):148–56. https://doi.org/10.1038/
bjc.2011.465.
 60. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu 
L, Nerini IF, et  al. Resistance to platinum-based 
chemotherapy is associated with epithelial to mes-
enchymal transition in epithelial ovarian cancer. Eur 
J Cancer. 2013;49:520–30. https://doi.org/10.1016/j.
ejca.2012.06.026.
 61. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate 
AD, Chaskar PD, Doiphode RY, et al. Snail and slug 
mediate radioresistance and chemoresistance by 
antagonizing p53-mediated apoptosis and acquiring 
a stem-like phenotype in ovarian cancer cells. Stem 
Cells. 2009;27:2059–68. https://doi.org/10.1002/
stem.154.
 62. Sandberg CJ, Altschuler G, Jeong J, Stromme KK, 
Stangeland B, Murrell W, et al. Comparison of gli-
oma stem cells to neural stem cells from the adult 
human brain identifies dysregulated Wnt- signaling 
and a fingerprint associated with clinical outcome. 
Exp Cell Res. 2013;319(14):2230–43. https://doi.
org/10.1016/j.yexcr.2013.06.004.
 63. Ortensi B, Setti M, Osti D, Pelicci G. Cancer stem 
cell contribution to glioblastoma invasiveness. Stem 
Cell Res Ther. 2013;4(1):18. https://doi.org/10.1186/
scrt166.
 64. Murat A, Migliavacca E, Gorlia T, Lambiv WL, 
Shay T, Hamou MF, et  al. Stem cell-related “self- 
renewal” signature and high epidermal growth fac-
tor receptor expression associated with resistance 
to concomitant chemoradiotherapy in glioblastoma. 
J  Clin Oncol. 2008;26(18):3015–24. https://doi.
org/10.1200/JCO.2007.15.7164.
 65. Colman H, Zhang L, Sulman EP, McDonald JM, 
Shooshtari NL, Rivera A, et al. A multigene predic-
tor of outcome in glioblastoma. Neuro-Oncology. 
2010;12(1):49–57. https://doi.org/10.1093/neuonc/
nop007.
 66. Bhat KPL, Balasubramaniyan V, Vaillant B, 
Ezhilarasan R, Hummelink K, Hollingsworth F, 
et  al. Mesenchymal differentiation mediated by 
NF-kappaB promotes radiation resistance in glio-
blastoma. Cancer Cell. 2013;24(3):331–46. https://
doi.org/10.1016/j.ccr.2013.08.001.
 67. Somarelli JA, Shetler S, Jolly MK, Wang X, Bartholf 
Dewitt S, Hish AJ, et  al. Mesenchymal-epithelial 
transition in sarcomas is controlled by the combi-
natorial expression of microRNA 200s and GRHL2. 
Mol Cell Biol. 2016;36(19):2503–13. https://doi.
org/10.1128/MCB.00373-16.
 68. Shen A, Zhang Y, Yang H, Xu R, Huang 
G.  Overexpression of ZEB1 relates to metasta-
sis and invasion in osteosarcoma. J  Surg Oncol. 
2012;105:830–4. https://doi.org/10.1002/jso.23012.
 69. Alba-Castellón L, Batlle R, Francí C, Fernández- 
Aceñero MJ, Mazzolini R, Peña R, et  al. 
Snail1 expression is required for sarcomagen-
esis. Neoplasia. 2014;16:413–21. https://doi.
org/10.1016/j.neo.2014.05.002.
 70. Wang N, Qi Y, Zou H, Zhang W-J, Li F, Pang L-J, 
et  al. Down-regulated E-cadherin expression is 
associated with poor five-year overall survival in 
bone and soft tissue sarcoma: results of a meta- 
analysis. PLoS One. 2015;10:e0121448. https://doi.
org/10.1371/journal.pone.0121448.
 71. Grosshans J, Wieschaus E. A genetic link between 
morphogenesis and cell division during forma-
tion of the ventral furrow in Drosophila. Cell. 
2000;101(5):523–31.
 72. Mata J, Curado S, Ephrussi A, Rorth P. Tribbles coor-
dinates mitosis and morphogenesis in Drosophila 
by regulating string/CDC25 proteolysis. Cell. 
2000;101(5):511–22.
 73. Murakami MS.  Morphogenesis during Xenopus 
gastrulation requires Wee1-mediated inhibition of 
cell proliferation. Development. 2004;131:571–80. 
https://doi.org/10.1242/dev.00971.
 74. Seher TC, Leptin M. Tribbles, a cell-cycle brake that 
coordinates proliferation and morphogenesis during 
R. Burr et al.
29
Drosophila gastrulation. Curr Biol. 2000;10:623–9. 
https://doi.org/10.1016/S0960-9822(00)00502-9.
 75. Comaills V, Kabeche L, Morris R, Buisson R, 
Yu M, Madden MW, et  al. Genomic instability is 
induced by persistent proliferation of cells under-
going epithelial-to-mesenchymal transition. Cell 
Rep. 2016;17:2632–47. https://doi.org/10.1016/j.
celrep.2016.11.022.
 76. Gruenbaum Y, Foisner R.  Lamins: nuclear inter-
mediate filament proteins with fundamental func-
tions in nuclear mechanics and genome regulation. 
Annu Rev Biochem. 2015;84:131–64. https://doi.
org/10.1146/annurev-biochem-060614-034115.
 77. Guttinger S, Laurell E, Kutay U.  Orchestrating 
nuclear envelope disassembly and reassembly dur-
ing mitosis. Nat Rev Mol Cell Biol. 2009;10(3):178–
91. https://doi.org/10.1038/nrm2641.
 78. Gao C, Su Y, Koeman J, Haak E, Dykema K, 
Essenberg C, et  al. Chromosome instability drives 
phenotypic switching to metastasis. Proc Natl Acad 
Sci U S A. 2016;113(51):14793–8. https://doi.
org/10.1073/pnas.1618215113.
 79. Knouse KA, Lopez KE, Bachofner M, Amon 
A.  Chromosome segregation fidelity in epithelia 
requires tissue architecture. Cell. 2018;175(1):200- 
11 e13. https://doi.org/10.1016/j.cell.2018.07.042.
 80. Diepenbruck M, Christofori G.  Epithelial- 
mesenchymal transition (EMT) and metastasis: yes, 
no, maybe? Curr Opin Cell Biol. 2016;43:7–13. 
https://doi.org/10.1016/j.ceb.2016.06.002.
 81. Shaul YD, Freinkman E, Comb WC, Cantor JR, Tam 
WL, Thiru P, et al. Dihydropyrimidine accumulation 
is required for the epithelial-mesenchymal transition. 
Cell. 2014;158:1094–109. https://doi.org/10.1016/j.
cell.2014.07.032.
 82. Yang J, Mani SA, Donaher JL, Ramaswamy S, 
Itzykson RA, Come C, et al. Twist , a master regulator 
of morphogenesis , plays an essential role in tumor 
metastasis Ben Gurion University of the Negev. 
Cell. 2004;117:927–39. https://doi.org/10.1016/j.
cell.2004.06.006.
 83. Tsai JH, Donaher JL, Murphy DA, Chau S, 
Yang J.  Spatiotemporal regulation of epithelial- 
mesenchymal transition is essential for squamous cell 
carcinoma metastasis. Cancer Cell. 2012;22(6):725–
36. https://doi.org/10.1016/j.ccr.2012.09.022.
 84. Trimboli AJ, Fukino K, de Bruin A, Wei G, 
Shen L, Tanner SM, et  al. Direct evidence for 
epithelial- mesenchymal transitions in breast can-
cer. Cancer Res. 2008;68(3):937–45. https://doi.
org/10.1158/0008-5472.CAN-07-2148.
 85. Rhim AD, Mirek ET, Aiello NM, Maitra A, 
Bailey JM, McAllister F, et  al. EMT and dis-
semination precede pancreatic tumor formation. 
Cell. 2012;148:349–61. https://doi.org/10.1016/j.
cell.2011.11.025.
 86. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, 
Cano A, Moreno-Bueno G, Palacios J.  Epithelial- 
mesenchymal transition in breast cancer relates 
to the basal-like phenotype. Cancer Res. 
2008;68(4):989–97. https://doi.org/10.1158/0008-
5472.CAN-07-2017.
 87. McCart Reed AE, Kutasovic JR, Vargas AC, 
Jayanthan J, Al-Murrani A, Reid LE, et al. An epi-
thelial to mesenchymal transition programme does 
not usually drive the phenotype of invasive lobular 
carcinomas. J Pathol. 2016;238:489–94. https://doi.
org/10.1002/path.4668.
 88. Alix-Panabieres C, Mader S, Pantel K.  Epithelial- 
mesenchymal plasticity in circulating tumor cells. 
J  Mol Med (Berl). 2017;95(2):133–42. https://doi.
org/10.1007/s00109-016-1500-6.
 89. Francart ME, Lambert J, Vanwynsberghe AM, 
Thompson EW, Bourcy M, Polette M, et  al. 
Epithelial-mesenchymal plasticity and circulating 
tumor cells: travel companions to metastases. Dev 
Dyn. 2018;247(3):432–50. https://doi.org/10.1002/
dvdy.24506.
 90. Zhang Z, Fan W, Deng Q, Tang S, Wang P, Xu P, 
et  al. The prognostic and diagnostic value of cir-
culating tumor cells in bladder cancer and upper 
tract urothelial carcinoma: a meta- analysis of 30 
published studies. Oncotarget. 2017;8:59527–38. 
https://doi.org/10.18632/oncotarget.18521.
 91. Khoo BL, Lee SC, Kumar P, Tan TZ, Warkiani ME, 
Ow SG, et al. Short-term expansion of breast circu-
lating cancer cells predicts response to anti-cancer 
therapy. Oncotarget. 2015;6(17):15578–93. https://
doi.org/10.18632/oncotarget.3903.
 92. Thiery JP, Lim CT. Tumor dissemination: an EMT 
affair. Cancer Cell. 2013;23(3):272–3. https://doi.
org/10.1016/j.ccr.2013.03.004.
 93. Chen Y-Y, Ma L, Gong W-F, Zhong J-H, Han Z-G, 
Qi L-N, et  al. Circulating tumor cells undergoing 
EMT provide a metric for diagnosis and prognosis of 
patients with hepatocellular carcinoma. Cancer Res. 
2018;78:4731–44. https://doi.org/10.1158/0008-
5472.can-17-2459.
 94. Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, et  al. 
Classification of circulating tumor cells by 
epithelial- mesenchymal transition markers. PLoS 
ONE. 2015;10:1–14. https://doi.org/10.1371/jour-
nal.pone.0123976.
 95. Zhao X-H, Wang Z-R, Chen C-L, Di L, Bi Z-F, 
Li Z-H, et  al. Molecular detection of epithelial- 
mesenchymal transition markers in circulating tumor 
cells from pancreatic cancer patients: Potential 
role in clinical practice. World J  Gastroenterol. 
2019;25:138–50. https://doi.org/10.3748/wjg.v25.
i1.138.
 96. Hodara E, Morrison G, Cunha A, Zainfeld D, Xu T, 
Xu Y et  al. Multiparametric liquid biopsy analysis 
in metastatic prostate cancer. JCI Insight. 2019;4(5). 
https://doi.org/10.1172/jci.insight.125529.
 97. Chistiakov DA, Chekhonin VP.  Circulating tumor 
cells and their advances to promote cancer metas-
tasis and relapse, with focus on glioblastoma mul-
tiforme. Exp Mol Pathol. 2018;105:166–74. https://
doi.org/10.1016/j.yexmp.2018.07.007.
2 Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis
30
 98. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig 
R, Kasimir-Bauer S.  Stem cell and epithelial- 
mesenchymal transition markers are frequently 
overexpressed in circulating tumor cells of meta-
static breast cancer patients. Breast Cancer Res. 
2009;11(4):R46.
 99. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, 
Bitting RL, Turnbull JD, et  al. Circulating tumor 
cells from patients with advanced prostate and 
breast cancer display both epithelial and mesenchy-
mal markers. Mol Cancer Res. 2011;9(8):997–1007. 
https://doi.org/10.1158/1541-7786.MCR-10-0490.
 100. Gradilone A, Raimondi C, Nicolazzo C, Petracca 
A, Gandini O, Vincenzi B, et al. Circulating tumor 
cells lacking cytokeratin in breast cancer: the impor-
tance of being mesenchymal. J  Cell Mol Med. 
2011;15:1066–70.
 101. Kallergi G, Papadaki MA, Politaki E, Mavroudis 
D, Georgoulias V, Agelaki S.  Epithelial to mesen-
chymal transition markers expressed in circulating 
tumour cells of early and metastatic breast can-
cer patients. Breast Cancer Res. 2011;13(3):R59. 
https://doi.org/10.1186/bcr2896.
 102. Markou A, Strati A, Malamos N, Georgoulias V, 
Lianidou ES. Molecular characterization of circulat-
ing tumor cells in breast cancer by a liquid bead array 
hybridization assay. Clin Chem. 2011;57(3):421–30. 
https://doi.org/10.1373/clinchem.2010.154328.
 103. Raimondi C, Gradilone A, Naso G, Vincenzi 
B, Petracca A, Nicolazzo C, et  al. Epithelial- 
mesenchymal transition and stemness features in 
circulating tumor cells from breast cancer patients. 
Breast Cancer Res Treat. 2011;130:449–55.
 104. Strati A, Markou A, Parisi C, Politaki E, Mavroudis 
D, Georgoulias V, et  al. Gene expression pro-
file of circulating tumor cells in breast cancer by 
RT-qPCR.  BMC Cancer. 2011;11:422. https://doi.
org/10.1186/1471-2407-11-422.
 105. Barriere G, Riouallon A, Renaudie J, Tartary 
M, Rigaud M.  Mesenchymal and stemness cir-
culating tumor cells in early breast cancer diag-
nosis. BMC Cancer. 2012;12:114. https://doi.
org/10.1186/1471-2407-12-114.
 106. Barriere G, Riouallon A, Renaudie J, Tartary M, 
Rigaud M.  Mesenchymal characterization: alterna-
tive to simple CTC detection in two clinical trials. 
Anticancer Res. 2012;32(8):3363–9.
 107. Giordano A, Gao H, Anfossi S, Cohen E, Mego 
M, Lee BN, et  al. Epithelial-mesenchymal tran-
sition and stem cell markers in patients with 
HER2-positive metastatic breast cancer. Mol 
Cancer Ther. 2012;11(11):2526–34. https://doi.
org/10.1158/1535-7163.
 108. Kasimir-Bauer S, Hoffmann O, Wallwiener D, 
Kimmig R, Fehm T.  Expression of stem cell and 
epithelial-mesenchymal transition markers in pri-
mary breast cancer patients with circulating tumor 
cells. Breast Cancer Res. 2012;14(1):R15. https://
doi.org/10.1186/bcr3099.
 109. Mego M, Gao H, Lee BN, Cohen EN, Tin S, 
Giordano A, et  al. Prognostic value of EMT- 
circulating tumor cells in metastatic breast cancer 
patients undergoing high-dose chemotherapy with 
autologous hematopoietic stem cell transplantation. 
J  Cancer. 2012;3:369–80. https://doi.org/10.7150/
jca.5111.
 110. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen 
EN, et  al. Expression of epithelial- mesenchymal 
transition-inducing transcription factors in primary 
breast cancer: the effect of neoadjuvant therapy. 
Int J  Cancer. 2012;130(4):808–16. https://doi.
org/10.1002/ijc.26037.
 111. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger 
A, Schillert A, Vogel V, et al. Identification of a pop-
ulation of blood circulating tumor cells from breast 
cancer patients that initiates metastasis in a xeno-
graft assay. Nat Biotechnol. 2013;31(6):539–44. 
https://doi.org/10.1038/nbt.2576.
 112. Cierna Z, Mego M, Janega P, Karaba M, Minarik 
G, Benca J, et  al. Matrix metalloproteinase 1 
and circulating tumor cells in early breast can-
cer. BMC Cancer. 2014;14:472. https://doi.
org/10.1186/1471-2407-14-472.
 113. Markiewicz A, Ksiazkiewicz M, Welnicka- 
Jaskiewicz M, Seroczynska B, Skokowski J, Szade 
J, et  al. Mesenchymal phenotype of CTC-enriched 
blood fraction and lymph node metastasis formation 
potential. PLoS One. 2014;9(4):e93901. https://doi.
org/10.1371/journal.pone.0093901.
 114. Markiewicz A, Welnicka-Jaskiewicz M, 
Seroczynska B, Skokowski J, Majewska H, Szade 
J, et  al. Epithelial-mesenchymal transition mark-
ers in lymph node metastases and primary breast 
tumors – relation to dissemination and proliferation. 
Am J Transl Res. 2014;6(6):793–808.
 115. Papadaki MA, Kallergi G, Zafeiriou Z, Manouras 
L, Theodoropoulos PA, Mavroudis D, et  al. 
Co-expression of putative stemness and epithelial- 
to- mesenchymal transition markers on single cir-
culating tumour cells from patients with early and 
metastatic breast cancer. BMC Cancer. 2014;14:651. 
https://doi.org/10.1186/1471-2407-14-651.
 116. Serrano MJ, Ortega FG, Alvarez-Cubero MJ, Nadal 
R, Sanchez-Rovira P, Salido M, et  al. EMT and 
EGFR in CTCs cytokeratin negative non-metastatic 
breast cancer. Oncotarget. 2014;5(17):7486–97. 
https://doi.org/10.18632/oncotarget.2217.
 117. Polioudaki H, Agelaki S, Chiotaki R, Politaki E, 
Mavroudis D, Matikas A, et al. Variable expression 
levels of keratin and vimentin reveal differential EMT 
status of circulating tumor cells and correlation with 
clinical characteristics and outcome of patients with 
metastatic breast cancer. BMC Cancer. 2015;15:1–
10. https://doi.org/10.1186/s12885-015-1386-7.
R. Burr et al.
31
 118. Satelli A, Brownlee Z, Mitra A, Meng QH, Li 
S. Circulating tumor cell enumeration with a com-
bination of epithelial cell adhesion molecule- and 
cell-surface vimentin-based methods for moni-
toring breast cancer therapeutic response. Clin 
Chem. 2015;61:259–66. https://doi.org/10.1373/
clinchem.2014.228122.
 119. Ueo H, Sugimachi K, Gorges TM, Bartkowiak K, 
Yokobori T, Muller V, et  al. Circulating tumour 
cell-derived plastin3 is a novel marker for predict-
ing long-term prognosis in patients with breast can-
cer. Br J Cancer. 2015;112(9):1519–26. https://doi.
org/10.1038/bjc.2015.132.
 120. Wang HY, Ahn S, Kim S, Park S, Jung D, Park S, et al. 
Detection of circulating tumor cell-specific mark-
ers in breast cancer patients using the quantitative 
RT-PCR assay. Int J Clin Oncol. 2015;20(5):878–90. 
https://doi.org/10.1007/s10147-015-0798-3.
 121. Bourcy M, Suarez-Carmona M, Lambert J, 
Francart ME, Schroeder H, Delierneux C, et  al. 
Tissue factor induced by epithelial-mesenchymal 
transition triggers a procoagulant state that drives 
metastasis of circulating tumor cells. Cancer Res. 
2016;76(14):4270–82. https://doi.org/10.1158/0008-
5472.can-15-2263.
 122. Bulfoni M, Gerratana L, Del Ben F, Marzinotto 
S, Sorrentino M, Turetta M, et  al. In patients with 
metastatic breast cancer the identification of cir-
culating tumor cells in epithelial-to-mesenchymal 
transition is associated with a poor prognosis. Breast 
Cancer Res. 2016;18(1):30. https://doi.org/10.1186/
s13058-016-0687-3.
 123. Hensler M, Vancurova I, Becht E, Palata O, Strnad P, 
Tesarova P, et al. Gene expression profiling of circu-
lating tumor cells and peripheral blood mononuclear 
cells from breast cancer patients. Oncoimmunology. 
2016;5(4):e1102827. https://doi.org/10.1080/21624
02x.2015.1102827.
 124. Hyun KA, Koo GB, Han H, Sohn J, Choi W, Kim 
SI, et al. Epithelial-to-mesenchymal transition leads 
to loss of EpCAM and different physical properties 
in circulating tumor cells from metastatic breast can-
cer. Oncotarget. 2016;7(17):24677–87. https://doi.
org/10.18632/oncotarget.8250.
 125. Reijm EA, Sieuwerts AM, Smid M, Vries JB, 
Mostert B, Onstenk W, et  al. An 8-gene mRNA 
expression profile in circulating tumor cells predicts 
response to aromatase inhibitors in metastatic breast 
cancer patients. BMC Cancer. 2016;16:123. https://
doi.org/10.1186/s12885-016-2155-y.
 126. Horimoto Y, Tokuda E, Murakami F, Uomori T, 
Himuro T, Nakai K, et  al. Analysis of circulating 
tumour cell and the epithelial mesenchymal transi-
tion (EMT) status during eribulin-based treatment 
in 22 patients with metastatic breast cancer: a pilot 
study. J  Transl Med. 2018;16(1):287. https://doi.
org/10.1186/s12967-018-1663-8.
 127. Guan X, Ma F, Li C, Wu S, Hu S, Huang J, et  al. 
The prognostic and therapeutic implications of cir-
culating tumor cell phenotype detection based on 
epithelial- mesenchymal transition markers in the 
first-line chemotherapy of HER2-negative metastatic 
breast cancer. Cancer Commun. 2019;39:1–10. 
https://doi.org/10.1186/s40880-018-0346-4.
 128. Markiewicz A, Topa J, Nagel A, Skokowski J, 
Seroczynska B, Stokowy T et  al. Spectrum of 
epithelial- mesenchymal transition phenotypes in 
circulating tumour cells from early breast can-
cer patients. Cancer. 2019;11(1). https://doi.
org/10.3390/cancers11010059.
 129. Pastushenko I, Brisebarre A, Sifrim A, Fioramonti 
M, Revenco T, Boumahdi S et  al. Identification 
of the tumour transition states occurring during 
EMT.  Nature. 2018;556. https://doi.org/10.1038/
s41586-018-0040-3.
 130. Grigore AD, Jolly MK, Jia D, Farach-Carson MC, 
Levine H. Tumor budding: the name is EMT. Partial 
EMT. J Clin Med. 2016;5(5). https://doi.org/10.3390/
jcm5050051.
 131. Jolly MK, Tripathi SC, Somarelli JA, 
Hanash SM, Levine H.  Epithelial/mesen-
chymal plasticity: how have quantitative 
mathematical models helped improve our under-
standing? Mol Oncol. 2017;11:739–54. https://doi.
org/10.1002/1878-0261.12084.
 132. Arnoux V, Nassour M, L'Helgoualc'h A, Hipskind 
RA, Savagner P.  Erk5 controls Slug expression 
and keratinocyte activation during wound healing. 
Mol Biol Cell. 2008;19(11):4738–49. https://doi.
org/10.1091/mbc.E07-10-1078.
 133. Blanco MJ, Barrallo-Gimeno A, Acloque H, 
Reyes AE, Tada M, Allende ML, et  al. Snail1a 
and Snail1b cooperate in the anterior migration of 
the axial mesendoderm in the zebrafish embryo. 
Development. 2007;134(22):4073–81. https://doi.
org/10.1242/dev.006858.
 134. Futterman MA, Garcia AJ, Zamir EA. Evidence for 
partial epithelial-to-mesenchymal transition (pEMT) 
and recruitment of motile blastoderm edge cells dur-
ing avian epiboly. Dev Dyn. 2011;240(6):1502–11. 
https://doi.org/10.1002/dvdy.22607.
 135. Grande MT, Sanchez-Laorden B, Lopez-Blau C, De 
Frutos CA, Boutet A, Arevalo M, et al. Snail1-induced 
partial epithelial-to-mesenchymal transition drives 
renal fibrosis in mice and can be targeted to reverse 
established disease. Nat Med. 2015;21(9):989–97. 
https://doi.org/10.1038/nm.3901.
 136. Leroy P, Mostov KE. Slug is required for cell sur-
vival during partial epithelial-mesenchymal transi-
tion of HGF-induced tubulogenesis. Mol Biol Cell. 
2007;18(5):1943–52. https://doi.org/10.1091/mbc.
e06-09-0823.
 137. Lovisa S, LeBleu VS, Tampe B, Sugimoto H, 
Vadnagara K, Carstens JL, et  al. Epithelial-to- 
mesenchymal transition induces cell cycle arrest 
and parenchymal damage in renal fibrosis. Nat Med. 
2015;21(9):998–1009. https://doi.org/10.1038/
nm.3902.
2 Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis
32
 138. van Helvert S, Storm C, Friedl P. Mechanoreciprocity 
in cell migration. Nat Cell Biol. 2018;20(1):8–20. 
https://doi.org/10.1038/s41556-017-0012-0.
 139. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, 
Wittner BS, Spencer JA, et al. Circulating tumor cell 
clusters are oligoclonal precursors of breast cancer 
metastasis. Cell. 2014;158:1110–22. https://doi.
org/10.1016/j.cell.2014.07.013.
 140. Au SH, Storey BD, Moore JC, Tang Q, Chen Y-L, 
Javaid S, et  al. Clusters of circulating tumor cells 
traverse capillary-sized vessels. Proc Natl Acad 
Sci. 2016;113:4947–52. https://doi.org/10.1073/
pnas.1524448113.
 141. Suo Y, Xie C, Zhu X, Fan Z, Yang Z, He H, et al. 
Proportion of circulating tumor cell clusters 
increases during cancer metastasis. Cytometry 
A. 2017;91(3):250–3. https://doi.org/10.1002/
cyto.a.23037.
 142. Murlidhar V, Reddy RM, Fouladdel S, Zhao L, 
Ishikawa MK, Grabauskiene S, et  al. Poor prog-
nosis indicated by venous circulating tumor cell 
clusters in early stage lung cancers. Cancer Res. 
2017;77:5194–206. https://doi.org/10.1158/0008-
5472.CAN-16-2072.
 143. Au SH, Edd J, Stoddard AE, Wong KHK, Fachin 
F, Maheswaran S, et  al. Microfluidic isolation of 
circulating tumor cell clusters by size and asymme-
try. Sci Rep. 2017;7:2433. https://doi.org/10.1038/
s41598-017-01150-3.
 144. Sarioglu AF, Aceto N, Kojic N, Donaldson MC, 
Zeinali M, Hamza B, et al. A microfluidic device for 
label-free, physical capture of circulating tumor cell 
clusters. Nat Methods. 2015;12:685–91. https://doi.
org/10.1038/nmeth.3404.
 145. Szczerba BM, Castro-Giner F, Vetter M, Krol I, 
Gkountela S, Landin J, et al. Neutrophils escort cir-
culating tumour cells to enable cell cycle progres-
sion. Nature. 2019;566(7745):553–7. https://doi.
org/10.1038/s41586-019-0915-y.
 146. Gkountela S, Castro-Giner F, Szczerba BM, Vetter 
M, Landin J, Scherrer R, et  al. Circulating tumor 
cell clustering shapes DNA methylation to enable 
metastasis seeding. Cell. 2019;176(1–2):98-112 e14. 
https://doi.org/10.1016/j.cell.2018.11.046.
 147. Thiery JP, Acloque H, Huang RYJ, Nieto 
MA. Epithelial-mesenchymal transitions in develop-
ment and disease. Cell. 2009;139:871–90. https://
doi.org/10.1016/j.cell.2009.11.007.
 148. Labelle M, Begum S, Hynes Richard O. Direct sig-
naling between platelets and cancer cells induces 
an epithelial-mesenchymal-like transition and pro-
motes metastasis. Cancer Cell. 2011;20:576–90. 
https://doi.org/10.1016/j.ccr.2011.09.009.
 149. Cheung KJ, Ewald AJ. A collective route to metas-
tasis: seeding by tumor cell clusters. Science 
(New York, NY). 2016;352:167–9. https://doi.
org/10.1126/science.aaf6546.
 150. Friedl P, Gilmour D.  Collective cell migration 
in morphogenesis, regeneration and cancer. Nat 
Rev Mol Cell Biol. 2009;10:445–57. https://doi.
org/10.1038/nrm2720.
 151. Cheung KJ, Padmanaban V, Silvestri V, Schipper 
K, Cohen JD, Fairchild AN, et al. Polyclonal breast 
cancer metastases arise from collective dissemina-
tion of keratin 14-expressing tumor cell clusters. 
Proc Natl Acad Sci U S A. 2016;113(7):E854–63. 
https://doi.org/10.1073/pnas.1508541113.
 152. Collisson EA, Sadanandam A, Olson P, Gibb WJ, 
Truitt M, Gu S, et  al. Subtypes of pancreatic duc-
tal adenocarcinoma and their differing responses to 
therapy. Nat Med. 2011;17(4):500–3. https://doi.
org/10.1038/nm.2344.
 153. Bailey P, Chang DK, Nones K, Johns AL, Patch 
AM, Gingras MC, et al. Genomic analyses identify 
molecular subtypes of pancreatic cancer. Nature. 
2016;531(7592):47–52. https://doi.org/10.1038/
nature16965.
 154. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza 
SG, Hoadley KA, et al. Virtual microdissection iden-
tifies distinct tumor- and stroma-specific subtypes 
of pancreatic ductal adenocarcinoma. Nat Genet. 
2015;47(10):1168–78. https://doi.org/10.1038/
ng.3398.
 155. Mitra A, Mishra L, Li S.  EMT, CTCs and CSCs 
in tumor relapse and drug-resistance. Oncotarget 
2015;6. https://doi.org/10.18632/oncotarget.4037.
 156. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang 
RY, et  al. Epithelial-mesenchymal transition spec-
trum quantification and its efficacy in decipher-
ing survival and drug responses of cancer patients. 
EMBO Mol Med. 2014;6(10):1279–93. https://doi.
org/10.15252/emmm.201404208.
 157. Tiwari N, Gheldof A, Tatari M, Christofori G. EMT 
as the ultimate survival mechanism of cancer cells. 
Semin Cancer Biol. 2012;22(3):194–207. https://
doi.org/10.1016/j.semcancer.2012.02.013.
 158. Frisch SM, Schaller M, Cieply B. Mechanisms that 
link the oncogenic epithelial-mesenchymal transition 
to suppression of anoikis. J  Cell Sci. 2013;126(Pt 
1):21–9. https://doi.org/10.1242/jcs.120907.
 159. Krawczyk N, Hartkopf A, Banys M, Meier-Stiegen 
F, Staebler A, Wallwiener M, et  al. Prognostic rel-
evance of induced and spontaneous apoptosis of 
disseminated tumor cells in primary breast cancer 
patients. BMC Cancer. 2014;14:394. https://doi.
org/10.1186/1471-2407-14-394.
 160. Chebouti I, Kasimir-Bauer S, Buderath P, Wimberger 
P, Hauch S, Kimmig R, et al. EMT-like circulating 
tumor cells in ovarian cancer patients are enriched 
by platinum-based chemotherapy. Oncotarget. 
2017;5:48820–31. https://doi.org/10.18632/
oncotarget.16179.
 161. Yokobori T, Iinuma H, Shimamura T, Imoto S, 
Sugimachi K, Ishii H, et  al. Plastin3 is a novel 
marker for circulating tumor cells undergoing the 
epithelial-mesenchymal transition and is associ-
ated with colorectal cancer prognosis. Cancer Res. 
2013;73(7):2059–69. https://doi.org/10.1158/0008-
5472.CAN-12-0326.
R. Burr et al.
33
 162. Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, 
Ozkumur E, et al. Microfluidic, marker-free isolation 
of circulating tumor cells from blood samples. Nat 
Protoc. 2014;9(3):694–710. https://doi.org/10.1038/
nprot.2014.044.
 163. Ge F, Zhang H, Wang DD, Li L, Lin PP. Enhanced 
detection and comprehensive in situ phenotypic char-
acterization of circulating and disseminated hetero-
ploid epithelial and glioma tumor cells. Oncotarget. 
2015;6(29):27049–64. https://doi.org/10.18632/
oncotarget.4819.
 164. Naume B, Borgen E, Tossvik S, Pavlak N, Oates 
D, Nesland JM.  Detection of isolated tumor cells 
in peripheral blood and in BM: evaluation of a new 
enrichment method. Cytotherapy. 2004;6(3):244–
52. https://doi.org/10.1080/14653240410006086.
 165. Wang ZP, Eisenberger MA, Carducci MA, Partin 
AW, Scher HI, Ts'o PO.  Identification and charac-
terization of circulating prostate carcinoma cells. 
Cancer. 2000;88(12):2787–95.
 166. Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, 
Yoshikawa T, Naito T et al. Size-based isolation of 
circulating tumor cells in lung cancer patients using 
a microcavity array system. PLoS ONE. 2013;8. 
https://doi.org/10.1371/journal.pone.0067466.
 167. Kim T-H, Lim M, Park J, Oh JM, Kim H, Jeong H, 
et  al. FAST: size-selective, clog-free isolation of 
rare cancer cells from whole blood at a liquid–liquid 
interface. Anal Chem. 2017;89:1155–62. https://doi.
org/10.1021/acs.analchem.6b03534.
 168. Hayashi M, Zhu P, McCarty G, Meyer CF, Pratilas 
CA, Levin A, et al. Size-based detection of sarcoma 
circulating tumor cells and cell clusters. Oncotarget. 
2017;8(45):78965–77. https://doi.org/10.18632/
oncotarget.20697.
 169. Rosenberg R, Gertler R, Friederichs J, Fuehrer K, 
Dahm M, Phelps R, et al. Comparison of two density 
gradient centrifugation systems for the enrichment 
of disseminated tumor cells in blood. Cytometry. 
2002;49:150–8. https://doi.org/10.1002/cyto.10161.
 170. Hou JM, Krebs M, Ward T, Sloane R, Priest L, 
Hughes A, et al. Circulating tumor cells as a window 
on metastasis biology in lung cancer. Am J Pathol. 
2011;178(3):989–96. https://doi.org/10.1016/j.
ajpath.2010.12.003.
 171. Gogoi P, Sepehri S, Zhou Y, Gorin MA, Paolillo 
C, Capoluongo E, et  al. Development of an auto-
mated and sensitive microfluidic device for cap-
turing and characterizing circulating tumor cells 
(CTCs) from clinical blood samples. PLoS One. 
2016;11:e0147400. https://doi.org/10.1371/journal.
pone.0147400.
 172. Kim YJ, Kang YT, Cho YH. Poly(ethylene glycol)-
modified tapered-slit membrane filter for effi-
cient release of captured viable circulating tumor 
cells. Anal Chem. 2016;88:7938–45. https://doi.
org/10.1021/acs.analchem.5b04927.
 173. Friedlander TW, Premasekharan G, Paris 
PL. Looking back, to the future of circulating tumor 
cells. Pharmacol Ther. 2014;142(3):271–80. https://
doi.org/10.1016/j.pharmthera.2013.12.011.
 174. Chen L, Peng M, Li N, Song Q, Yao Y, Xu B, et al. 
Combined use of EpCAM and FR α enables the 
high-efficiency capture of circulating tumor cells 
in non- small cell lung cancer. Sci Rep. 2018:1–10. 
https://doi.org/10.1038/s41598-018-19391-1.
 175. Cho EH, Wendel M, Luttgen M, Yoshioka C, 
Marrinucci D, Lazar D, et al. Characterization of cir-
culating tumor cell aggregates identified in patients 
with epithelial tumors. Phys Biol. 2012;9(1):016001. 
https://doi.org/10.1088/1478-3975/9/1/016001.
 176. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, 
Malchiodi M, Baehring F, et  al. Fluid biopsy in 
patients with metastatic prostate, pancreatic and 
breast cancers. Phys Biol. 2012;9(1):016003. https://
doi.org/10.1088/1478-3975/9/1/016003.
 177. Kuhn P, Bruce RH, Ladanyi A, Lerner RA, Hsieh 
HB, Curry DN, et al. A rare-cell detector for cancer. 
Proc Natl Acad Sci. 2004;101:10501–4. https://doi.
org/10.1073/pnas.0404036101.
 178. Nagrath S, Sequist LV, Maheswaran S, Bell DW, 
Irimia D, Ulkus L, et  al. Isolation of rare circulat-
ing tumour cells in cancer patients by microchip 
technology. Nature. 2007;450:1235–9. https://doi.
org/10.1038/nature06385.
 179. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, 
Ulkus L, et al. Isolation and characterization of cir-
culating tumor cells from patients with localized and 
metastatic prostate. Cancer. 2010;2:25ra23.
 180. Zhao M, Wei B, Chiu DT.  Imaging multiple bio-
markers in captured rare cells by sequential 
immunostaining and photobleaching. Methods. 
2013;64(2):108–13. https://doi.org/10.1016/j.
ymeth.2013.08.006.
 181. Murlidhar V, Zeinali M, Grabauskiene S, Ghannad- 
Rezaie M, Wicha MS, Simeone DM, et al. A radial 
flow microfluidic device for ultra-high- throughput 
affinity-based isolation of circulating tumor 
cells. Small. 2014;10(23):4895–904. https://doi.
org/10.1002/smll.201400719.
 182. Magbanua MJM, Carey LA, DeLuca A, Hwang J, 
Scott JH, Rimawi MF, et al. Circulating tumor cell 
analysis in metastatic triple-negative breast cancers. 
Clin Cancer Res. 2015;21:1098–105. https://doi.
org/10.1158/1078-0432.CCR-14-1948.
 183. Kim MS, Sim TS, Kim YJ, Kim SS, Jeong H, Park 
J-M, et al. SSA-MOA: a novel CTC isolation plat-
form using selective size amplification (SSA) and a 
multi-obstacle architecture (MOA) filter. Lab Chip. 
2012;12:2874. https://doi.org/10.1039/c2lc40065k.
 184. Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das 
A, Liu X, et al. Flexible micro spring array device 
for high-throughput enrichment of viable circulating 
tumor cells. Clin Chem. 2014;60(2):323–33. https://
doi.org/10.1373/clinchem.2013.206805.
 185. Cabel L, Proudhon C, Gortais H, Loirat D, Coussy 
F, Pierga JY, et al. Circulating tumor cells: clinical 
validity and utility. Int J Clin Oncol. 2017;22(3):421–
30. https://doi.org/10.1007/s10147-017-1105-2.
2 Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis
34
 186. Patel V, Keating MJ, Wierda WG, Gandhi 
V.  Preclinical combination of TP-0903, an AXL 
inhibitor and B-PAC-1, a procaspase-activating com-
pound with ibrutinib in chronic lymphocytic leuke-
mia. Leuk Lymphoma. 2016;57:1494–7. https://doi.
org/10.3109/10428194.2015.1102243.
 187. Giannelli G, Villa E, Lahn M. Transforming growth 
factor-beta as a therapeutic target in hepatocellular 
carcinoma. Cancer Res. 2014;74(7):1890–4. https://
doi.org/10.1158/0008-5472.CAN-14-0243.
 188. Rodon J, Carducci M, Sepulveda-Sanchez JM, 
Azaro A, Calvo E, Seoane J, et al. Pharmacokinetic, 
pharmacodynamic and biomarker evaluation 
of transforming growth factor-beta receptor I 
kinase inhibitor, galunisertib, in phase 1 study 
in patients with advanced cancer. Investig New 
Drugs. 2015;33(2):357–70. https://doi.org/10.1007/
s10637-014-0192-4.
 189. Puls LN, Eadens M, Messersmith W.  Current sta-
tus of SRC inhibitors in solid tumor malignan-
cies. Oncologist. 2011;16(5):566–78. https://doi.
org/10.1634/theoncologist.2010-0408.
 190. Hospital ZPPs. Aspirin on CTCs of advanced breast 
and colorectal cancer. 2015. https://ClinicalTrials.
gov/show/NCT02602938
 191. Biotherapeutics A.  Phase I dose escalation study 
of AB-16B5  in subjects with an advanced solid 
malignancy. 2015. https://ClinicalTrials.gov/show/
NCT02412462
 192. Tolero Pharmaceuticals I.  First-in-human study of 
oral TP-0903 (a Novel Inhibitor of AXL Kinase) in 
patients with advanced solid tumors. 2016. https://
ClinicalTrials.gov/show/NCT02729298.
 193. Alderton GK.  Metastasis: epithelial to mesenchy-
mal and back again. Nat Rev Cancer. 2013;13(1):3. 
https://doi.org/10.1038/nrc3428.
 194. Brabletz T. To differentiate or not – routes towards 
metastasis. Nat Rev Cancer. 2012;12:425–36. 
https://doi.org/10.1038/nrc3265.
 195. Beerling E, Seinstra D, de Wit E, Kester L, van der 
Velden D, Maynard C, et al. Plasticity between epi-
thelial and mesenchymal states unlinks EMT from 
metastasis-enhancing stem cell capacity. Cell Rep. 
2016;14(10):2281–8. https://doi.org/10.1016/j.
celrep.2016.02.034.
 196. Nieto MA.  Epithelial plasticity: a common 
theme in embryonic and cancer cells. Science. 
2013;342(6159):1234850. https://doi.org/10.1126/
science.1234850.
 197. Maheswaran S, Haber DA. Ex vivo culture of CTCs: 
an emerging resource to guide cancer therapy. Cancer 
Res. 2015;75:2411–6. https://doi.org/10.1158/0008-
5472.CAN-15-0145.
R. Burr et al.
